Dual-Receptor Agonism: What the Human Trials Actually Show

For two decades, GLP-1 receptor research dominated the metabolic literature. Liraglutide came first, then semaglutide. Both reduced body weight in clinical trials by single digits — meaningful, but modest. The narrative on what was possible with incretin pharmacology held steady at "useful, not transformative."

The dual-agonist data changed that narrative.

In SURMOUNT-1, the phase 3 trial of tirzepatide in 2,539 adults with obesity and without type 2 diabetes, participants on the highest dose lost an average of 22.5% of their body weight over 72 weeks. That number alone was unprecedented for a non-surgical intervention. But it was not the most surprising finding.

The most surprising finding was retatrutide.

In its phase 2 trial — published in the New England Journal of Medicine in 2023 — adults with obesity on retatrutide's highest dose lost an average of 24.2% of body weight at 48 weeks. That trajectory had not plateaued at the 48-week endpoint. Conservatively, the body of work suggests the real ceiling on retatrutide's weight reduction is somewhere meaningfully higher than what any single-receptor compound in this space has produced.

This piece walks through the receptor biology, the trial data published in humans, and three nuanced points about these compounds that do not appear in the marketing literature but matter a great deal in practice.

The receptor pair, plus glucagon

GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) are both incretin hormones. They are released by the gut after eating and they both signal through G-protein-coupled receptors on pancreatic beta cells. They share a developmental origin but have diverged in tissue distribution and downstream effects.

GLP-1 receptors are dense in the central nervous system regions that govern appetite — the arcuate nucleus, the area postrema, the nucleus of the solitary tract. Activation here suppresses hunger signaling. GIP receptors, by contrast, have broader expression in adipose tissue, bone, and other peripheral compartments.

Tirzepatide is a single 39-amino-acid peptide that activates both. Retatrutide goes one step further — it activates GLP-1, GIP, and glucagon receptors simultaneously. The glucagon component is what changes the energy equation, because glucagon receptor activation increases resting energy expenditure. Tirzepatide reduces calorie intake. Retatrutide reduces intake and increases output.

What the human studies actually report

The published human evidence is now substantial. A few anchor points:

**Tirzepatide for obesity (SURMOUNT-1, NEJM 2022).** 22.5% mean weight loss at the 15mg dose at 72 weeks. 91% of participants on the highest dose achieved 5%+ loss. Half achieved 20%+ loss.

**Tirzepatide for type 2 diabetes (SURPASS series).** Across SURPASS-1 through SURPASS-5, tirzepatide produced larger HbA1c reductions and larger weight losses than the comparators (placebo, semaglutide, insulin). It is the strongest glycemic agent in the modern type-2-diabetes arsenal.

**Tirzepatide for cardiovascular outcomes (SUMMIT, NEJM 2024).** In adults with obesity-related heart failure with preserved ejection fraction, tirzepatide reduced a composite cardiovascular endpoint and improved quality-of-life scores. Heart failure with preserved ejection fraction is one of the most stubborn cardiovascular conditions in modern medicine — this finding is meaningful.

**Retatrutide for obesity (NEJM 2023, phase 2).** 24.2% mean weight loss at 48 weeks at the 12mg dose. The dose-response curve had not plateaued. Phase 3 data is in progress.

**Retatrutide for hepatic steatosis.** In a substudy of the phase 2 obesity trial, liver fat content dropped 86% on the highest dose. NAFLD (fatty liver disease) is the most common chronic liver condition in the developed world.

Three things people miss

Most articles about these compounds stop here. The trial data is dramatic enough that the practical implications get glossed over. Three angles worth understanding:

### 1. Lean mass preservation is not automatic.

In SURMOUNT-1, body composition substudies showed that approximately 25% of total weight loss was lean mass. That ratio matters. People who lose weight without protecting muscle end up with worse metabolic outcomes long-term — lower resting metabolic rate, lower insulin sensitivity, lower physical capacity.

The published evidence is consistent: combining a GLP-1 / GIP agonist with adequate protein intake (1.2 to 1.6 grams of protein per kilogram of goal body weight, per day) and resistance training preserves substantially more lean mass than the compound alone. The compound is doing the appetite-and-energy-balance work; the resistance stimulus and protein are doing the muscle-preservation work. Both pieces are needed.

### 2. The metabolic re-set persists, somewhat.

The follow-up data and several smaller observational studies suggest that some metabolic improvements persist after discontinuation — improved insulin sensitivity, lower fasting glucose, better lipid panels — even as body weight partially rebounds. The compound is not only treating a steady-state symptom; it is resetting metabolic regulation.

The practical implication is that the goal of the intervention is not "lose weight forever on this peptide." The goal is to use a defined window of intervention to re-establish a healthier metabolic baseline, then transition to maintenance through nutrition and training. Several published case series describe this approach with maintenance dose tapering rather than abrupt discontinuation.

### 3. Retatrutide changes the energy expenditure side of the equation.

Tirzepatide users frequently describe reduced appetite and food noise — the cognitive volume around eating quiets down. Retatrutide users report this and describe a noticeable thermogenic effect: warmer body temperature, slightly elevated resting heart rate, more energy for daily activity. This is the glucagon receptor component doing its work.

What the research-investigator field is doing

The published clinical trial protocols are useful starting points for understanding how these compounds behave at different doses. Most published research has used 2.5mg as a starting dose with titration upward by 2.5mg increments every four weeks based on tolerance, with the dose-limiting consideration being gastrointestinal effects (nausea, fullness) rather than cardiovascular or hepatic safety, which were essentially clean across the trial dataset.

The compounds are typically reconstituted with bacteriostatic water and stored at 36 to 46 degrees Fahrenheit. Lyophilized peptide stability at this temperature is well-characterized. Reconstituted product retains potency for a defined window depending on storage conditions and pH.

Both compounds are restricted to laboratory research use only and are not for human consumption.

The compounds in our catalogue

Both tirzepatide and retatrutide are stocked at research-grade purity through our laboratory partner network. Each batch is independently HPLC and mass spectrometry verified. Certificates of Analysis are available on every SKU.

The dual-receptor and triple-receptor agonist family is the most active area in metabolic research literature today. The trial data is unambiguous. The practical implications — lean mass preservation, the metabolic re-set, the difference between dual and triple agonism — are what separate someone who understands these compounds from someone who has just heard of them.